Clinical Trial Update: Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping [Phase 2]

View source ↗

Summary

Phase 2 trial exploring precision treatment for HR+ HER2- advanced breast cancer using SNF molecular subtyping; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING